BioWorld-Insight-2010-03-15
Dimebon Bust 'No Surprise': Back to Drawing Board in AD
Dimebon Bust 'No Surprise': Back to Drawing Board in AD
Medivation Inc.'s stock-jolting Phase III blow-up with Dimebon (latrepirdine) for Alzheimer's disease imperiled the firm's deal with Pfizer Inc., triggered shareholder class-action lawsuits and upped the ante for already hard-pressed developers of AD therapies across the board.

